Search PubMed⌕ Search

Biomedical subjects

L Orö

Publications and source records attributed to L Orö.

At least 19 recordsLinked to original sources
PubMed1984

A comparison between meptazinol and dextropropoxyphene plus paracetamol in elderly patients with musculoskeletal pains.

The efficacy and acceptability of meptazinol and dextropropoxyphene plus paracetamol were compared in 32 elderly patients with various types of musculoskeletal pain. A double-blind crossover technique was used. After at least 1 week in hospital, the previous analgesic treatment was stopped and single-blind placebo was given for 1 day. Patients then received, at random, 5-days' treatment with either 200 mg meptazinol 4-times daily or 65 mg dextropropoxyphene plus 650 mg paracetamol 4-times daily before being crossed over to the alternative medication for a further 5 days. If necessary, up to 4 tablets a day were allowed of 500 mg aspirin plus 50 mg caffeine as a 'rescue' analgesic. Assessments were made before (on placebo) and at the end of each treatment period of pain severity and effect on patients' sleep, and details recorded of 'rescue' analgesic consumption and any side-effects. At the end of the trial, an overall assessment was made of the effectiveness and tolerance of each treatment and patients were asked which they preferred. The results showed that both treatments reduced pain severity significantly for all the parameters measured; however, most patients needed additional pain relief. Few side-effects were reported during either treatment period.

Acetaminophen↗
PubMed1982

Dose-response study of the effect of ciprofibrate on serum lipoprotein concentrations in hyperlipoproteinaemia.

The effect of ciprofibrate, 2[p-(2,2-dichlorocyclopropyl)-phenoxyl]-2-methyl propionic acid, in daily doses of 50, 100, and 200 mg was studied in 50 patients with hyperlipoproteinaemia (21 type IIA, 10 type IIB and 19 type IV). Ciprofibrate was convenient to take and was without subjective side effects. The greatest hypolipidaemic effects were reached for all lipoproteins with 200 mg daily. In type IIA and IIB, mean low density lipoprotein (LDL) cholesterol was normalized on the 200 mg dose. The effect was highly dependent on initial LDL cholesterol concentrations, decreases being observed above 4 mmol/l and increases below that concentration. Mean very low density lipoprotein (VLDL) triglyceride concentrations decreased on 200 mg per day by 48-59%. HDL cholesterol increased in all types of hyperlipoproteinaemia by 6-19%, the change being unrelated to changes in VLDL lipids. With a dosage of 200 mg daily the effects were maintained for the following period of 6 months. It is concluded from this study that it would be appropriate to start patients on 100 mg daily and then titrate their dose according to response. The optimal dosage for ciprofibrate seems to be 200 mg daily.

Alanine Transaminase↗
PubMed1982

Experience with nitrendipine--a new calcium antagonist--in hypertension.

The antihypertensive effect of 20 mg of nitrendipine (BAY e 5009) was compared with that of 40 mg, administered orally once daily to 12 patients with essential hypertension (WHO I-II). The study was designed as a double-blind, within-patient comparison. The present results indicate that nitrendipine has a significant antihypertensive effect both at 20 and 40 mg as compared to placebo. There was no significant change in heart rate with 20 mg of nitrendipine, whereas there was a significant increase in heart rate after the first dose of 40 mg. Nitrendipine in dosages of 20 mg and 40 mg daily was equally effective as regards the antihypertensive effect. This applies both to the early response (first day) and the late response (3 weeks). Side effects were common in the 40-mg treatment group, but rare in the 20-mg group; only one patient had headache (three times) during the 3-week treatment period. It can be concluded that in mild hypertension, treatment with 20 mg of nitrendipine once daily constitutes an effective antihypertensive therapy. In more severe cases of hypertension, however, combination treatment with beta-blockers, for example, and/or repeated daily administration of nitrendipine ought to be investigated.

Adult↗
PubMed1981

Treatment of angina pectoris with metoprolol. A comparison between Durules administered once daily and tablets administered twice daily.

Seventeen patients suffering from angina pectoris completed a double-blind trial comparing the efficacy and safety of metoprolol Durules administered once daily and metoprolol tablets administered twice daily both at a daily dosage of 200 mg. In terms of anginal attacks and nitroglycerine consumption, there was no difference between the two regimens. Neither the diurnal distribution of attacks nor the patient interview revealed any significant differences between the two regimens. Heart rate, blood pressure and plasma levels of metoprolol were also similar on conventional tablets 100 mg b.d. and Durules 200 mg once daily. These findings indicate that once daily administration of metoprolol Durules is an effective and safe therapy in angina pectoris.

Aged↗
PubMed1979

Antianginal efficiency of nifedipine with and without a beta-blocker, studied with exercise test. A double-blind, randomized subacute study.

Twenty-one patients, mean age 60.3 years, with stable angina pectoris earlier treated with beta-blockers, were investigated with standardized exercise tests to evaluate the action of nifedipine alone and in combination with a beta-blocker. The first exercise test was performed 3 weeks after treatment with the patient's usual beta-blocker. Following this, the patients were tested twice after a double-blind cross-over 3-week trial with nifedipine and placebo. The patients were subsequently treated for 3 weeks with nifedipine 10 mg 3 times daily or placebo and then performed an exercise test. During the 4th period of 3 weeks the patients took a combination of nifedipine, 10 mg 3 times daily, and their usual beta-blocker and then performed the final exercise test. Nifedipine alone raised the heart rate by 5 beats/min at rest and diminished the systolic blood pressure at rest by 17 mm Hg. During exercise at comparable load the heart rate did not change significantly, but the systolic blood pressure decreased with 22 mm Hg. The exercise tolerance expressed as total work increased on a average by 20%, range-14 - + 194%. Nifedipine in combination with a beta-blocker gave a further decrease in the systolic blood pressure, totally 37 mm Hg at comparable load. The exercise tolerance increased more, totally by an average of 41%. There was a significant correlation between basal values for systolic blood pressure registered during the placebo period at rest and the percentage change in total work. The atrioventricular conduction time did not change significantly compared to placebo during treatment with nifedipine or the combination nifedipine + beta-blocker. No serious side-effects were observed during the study.

Aged↗
PubMed1976

Measurement of cardiac output by impedance cardiography in patients with myocardial infarction. Comparative evaluation of impedance and dye dilution methods.

The cardiac output was measured simultaneously by the impedance cardiography and dye dilution methods in 10 patients with acute myocardial infarction 2-3 weeks after admission to the Coronary Care Unit. The impedance cardiac output was on the average 9.7% higher than the dye dilution cardiac output. The reproducibility of impedance cardiac output 4.1%, compared with 5.1% for the dye dilution method. The study showed a satisfactory reliability of impedance in predicting the relative changed of cardiac output in response to tilting from the supine to the 30 degrees head-up position, to a 10 degrees head-down position, and to the intravenous administration of propranolol.

Acute Disease↗
PubMed1976

The effects of different dose regimens of niceritrol of serum lipid concentrations in man.

The lipid-lowering effects of 3 g of the nicotinic acid derivative pentaerythritoltetranicotinate (niceritrol) given either 1 g X 3 or 1.5 g X 2 have been evaluated in 18 subjects with hyperlipoproteinaemia. When 1 g niceritrol was given three times daily, the serum TG concentration fell from 3.14 +/- 0.48 to 1.86 +/- 0.18 mmol/1 (41% reduction) and the serum cholesterol concentration from 282 +/- 9 to 227 +/- 11 mg/100 ml (20% reduction). The same daily dose, given 1.5 g twice, did not significantly lower the serum TG concentration, and serum cholesterol was lowered by only 12%. Niceritrol tablets prepared with a dissolution time of 60 or 90 min had identical lipid-lowering properties. Although patients may find it practical to take niceritrol only twice daily, such a dose regimen has considerably less effect on elevated serum lipids than a thrice-daily regimen.

Administration, Oral↗
PubMed1976

Serum lipid and lipoprotein concentrations in chronic uremia.

The concentrations of triglycerides and cholesterol have been determined in total serum and in the three major serum lipoprotein classes--very low (VLDL), low (LDL) and high (HDL) density lipoproteins-after an overnight fast in 39 patients with chronic uremia of more than 2 years' duration and with serum creatinine above 350 mumol/l. The values were compared with data from healthy male and female controls. The findings were similar for male and female uremics. Hypertriglyceridemia was common while serum cholesterol tended to be normal or subnormal. With the conventional typing system for hyperlipidemia, types II A, III and IV were present in 6,9 and 30%,respectively. The tryglyceride and cholesterol concentrations in VLDL were increased, while their normal relation for this lipoprotein class was maintained. In LDL the concentration of tryglycerides was increased, while that of cholesterol was low. The LDL composition, therefore, was changed to be more triglyceride-rich than normal. The changes in concentration and composition of LDL indicated that the levels of LDL 1 were raised and of LDL 2 decreased in chronic uremia. Increased levels of LDL tryglycerides occurred more frequently (40%) than increased levels of VLDL triglycerides (33%). The most striking and consistent lipoprotein abnormality was a low HDL cholesterol, which was not related to high VLDL levels. The HDL tryglycerides, on the other hand, tended to be somewhat high. The importance of the raised levels of the triglyceride-rich VLDL and LDL 1 and the decreased levels of HLD cholesterol for the rapid development of atherosclerotic vascular diseases which occur in chronic uremia is discussed. It is of interest in this context that both total cholesterol and LDL cholesterol were low. The possible mechanisms underlying the lipoprotein abnormalities in chronic uremia are discussed and it is suggested that they are complex.

Adult↗
PubMed1976

Effects of the cardioselective beta-adrenergic receptor blocking agent metoprolol in angina pectoris. Subacute study with exercise tests.

The effect of a cardioselective beta-adrenergic blocking agent, metoprolol, on symptoms and exercise tolerance was studied in 16 patients with angina pectoris. Metroprolol was compared with placebo at two dose levels (20 mg t.d.s. and 50 mg t.d.s.) in a double-blind trial in 14 patients. Compared with placebo, metroprolol caused a significant reduction of heart rate and systolic blood pressure during exercise, and consequently a reduction of the rate-pressure product. The reduction was greater with 50 mg t.d.s. than with 20 mg t.d.s. The exercise tolerance measured as total work increased significantly by 21 per cent during treatment with metroprolol 20 mg t.d.s., and by 17 per cent during treatment with 50 mg t.d.s. There was a reduction in the number of anginal attacks and in nitroglycerin consumption, and subjective improvement of angina pectoris at both dose levels of metroprolol. No signs of cardiac failure appeared during any of the four treatment periods. Heart volume showed no significant change. Unwanted effects were of the same frequency and severity during treatment with metroprolol at both dose levels as with placebo.

Adrenergic beta-Antagonists↗
PubMed1975

Exercise tolerance in patients with angina pectoris after pentaerythritol trinitrate and alprenolol studied by two different methods.

Exercise tolerance has been studied by two different methods, heart-rate-controlled exercise and stepwise increased load, in 12 patients with angina pectoris. The response to a beta-adrenergic blocking agent, alprenolol, and an alkyl nitrate derivative, pentaerythritol trinitrate (PETRIN) was studied by the two methods after double-blind administration of the drugs. Rating scales were used to quantitate the degree of dyspnoea, angina pectoris and tiredness in the legs. After PETRIN both methods showed significant increases in exercise tolerance (19 and 21 per cent). The heart-rate-controlled test showed a significant increase (33%) after alprenolol, but the change was not significant by the other method. In the patients studied, heart-rate-controlled exercise discriminated between active drug and placebo better than the stepwise increased load test, what might have been due to more optimal matching of the loads obtained in the heart-rate-controlled test. Indications are given about how to design an exercise study in patients with angina pectoris.

Aged↗
PubMed1975

Effect of quinidine on maintaining sinus rhythm after conversion of atrial fibrillation or flutter. A multicentre study from Stockholm.

In a controlled study comprising 176 patients, quinidine in the form of Kinidin Durules was found to reduced significantly the recurrence of the atrial fibrillation during a 1-year follow-up period after successful electric shock conversion. After one year, 51 per cent (52/101) of the patients in the quinidine group, and 28 per cent (21/75) in the control group remained in sinus rhythm (P smaller than 0.001). No less than 43 per cent of the patients converted to sinus rhythm during treatment with maintenance doses of quinidine sulphate before intended DC conversion. Gastrointestinal side-effects were not uncommon, and caused interruption of quinidine treatment in some cases.

Adult↗
PubMed1975

Cholestyramine, clofibrate and nicotinic acid as single or combined treatment of type IIa and IIb hyperlipoproteinaemia.

1. In type IIa and IIb hyperlipoproteinaemia, treatment with 16 g cholestyramine daily reduced the cholesterol concentration 23%. By adding clofibrate this effect was enhanced to a 29% reduction and at the same time clofibrate reduced the triglyceride (TG) concentration 33%. 2. The optimal cholesterol reduction with clofibrate in type II was 17% and was found after treatment with 1.5 g clofibrate/day. The optimal TG reduction appeared to be achieved with a daily dose of 2 g.3. Nicotinic acid in the form of niceritrol had another type of dose-response in type II with doses from 3 to 6 g/day. It appeared as if the optimal dose probably was above 6 g daily. The 6 g dose produced a cholesterol reduction of 22% and in type IIb there was at the same time a 50% reduction of the TG concentration. 4. By combining 3 g niceritrol with 2 g clofibrate almost the same effect on serum lipids was obtained as with 6 g niceritrol. When choosing a drug for treatment of hyperlipoproteinaemia it is necessary to consider not only the lipid lowering effect but also the side effects which are not discussed here. By combining clofibrate with either cholestyramine or niceritrol it was possible to improve the lipid lowering effect. There were no side effects which were not seen when the drugs were used alone. A more frequent use of combinations to improve the treatment of hyperlipoproteinaemia is recommended.

Cholestyramine Resin↗